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Lymphomatoid papulosis is part of a spectrum of
CD30+ cutaneous lymphoproliferative disorders char-
acterized by spontaneous tumor regression. The
mechanism(s) of regression is unknown. In a recent
study, a selective increase in CD30 ligand expression in
regressing lesions of lymphomatoid papulosis and
cutaneous CD30+ anaplastic large cell lymphoma was
shown, suggesting that activation of the CD30 signal-
ing pathway may be responsible for tumor regression,
whereas no difference in Fas/Fas ligand expression
was found between regressing and nonregressing
lesions. Therefore we tested the effects of CD30 and
Fas activation on three CD30+ cutaneous lymphoma
cell lines (Mac-1, Mac-2A, JK) derived from non-
regressing tumors of two patients who had progressed
from lymphomatoid papulosis to systemic anaplastic
large cell lymphoma. To evaluate the effects of CD30
signaling, the cell lines were incubated with a CD30
agonistic antibody, HeFi-1. Proliferative responses,
mitogen-activated protein kinase, and nuclear factor
kB activities were determined with and without CD30
activation. Mac-1 and Mac-2A showed increased pro-
liferative responses to incubation with CD30 activating
antibody, HeFi-1. Inhibition of the mitogen-activated
protein kinase activity caused growth inhibition of the
Mac-1, Mac-2A, and JK cell lines. Activation of the
Fas pathway induced apoptosis in all three cell lines.
Taken together, these ®ndings suggest that resistance
to CD30-mediated growth inhibition provides a
possible mechanism for escape of cutaneous anaplastic
large cell lymphoma from tumor regression. Mitogen-
activated protein kinase inhibitors are potential thera-
peutic agents for the treatment of advanced cutaneous
anaplastic large cell lymphoma. Key words: CD30/
cutaneous anaplastic large cell lymphoma/MAPK/NF-kB.
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P
rimary cutaneous CD30+ lymphoproliferative disorders
(LPD) are recognized as a distinct biologic entity in the
European Organization for Research and Treatment of
Cancer classi®cation of cutaneous lymphomas and the
forthcoming World Health Organization classi®cation of
lymphomas (Willemze et al, 1997; Jaffe et al, 1999). CD30+
cutaneous LPD are associated with frequent spontaneous regression
(Cabanillas et al, 1995; Paulli et al, 1995). Although cutaneous
CD30+ LPD generally have a good prognosis, certain cases
progress to aggressive systemic lymphomas and become resistant
to chemotherapy (Willemze and Beljaards, 1993; Paulli et al, 1995;
Willemze et al, 1997; Bekkenk et al, 2000).
CD30 antigen expression is a favorable prognostic factor in
cutaneous T cell lymphomas (Beljaards et al, 1993; Willemze et al,
1993; Paulli et al, 1995; Bekkenk et al, 2000). With the exception of
mycosis fungoides, CD30-negative T cell lymphomas of the skin
tend to have a more aggressive course and a poorer prognosis than
CD30+ cutaneous LPD.
Members of the tumor necrosis factor (TNF) receptor super-
family, such as Fas (CD95), TNF receptors types I and II, CD27,
CD30, CD40, DR3, DR4, and DR5 play an important role in
immune regulation. These members of the TNF receptor family
contain a ``death domain'' that triggers programmed cell death
when activated by the appropriate ligand (Ashkenazi and Dixit,
1998). Some members of the TNF receptor and ligand superfamily
are implicated in the pathogenesis of immune disorders and
lymphomas (Gruss and Dower, 1995). An important function of
the TNF members is regulation of growth and elimination of
peripheral T cells during their expansion in response to antigenic
stimuli. T cell apoptosis occurs in two major forms: antigen driven
and lymphokine withdrawal induced. Antigen-driven death is
induced by the activation of the T cell antigen receptor, and is
regulated by Fas and TNFRI (Lenardo et al, 1999). The speci®city
of T cell elimination by this pathway is partly due to a requirement
for simultaneous activation of T cell antigen receptor and the TNF
or Fas receptor (Lenardo et al, 1999).
The second mechanism of T cell elimination is cytokine-
withdrawal-induced cell death. In this pathway, T cells are
deprived of the cytokine support that is associated with the
antigen-induced activation state (Telford et al, 1997; Lenardo et al,
1999). This mechanism of apoptosis is prevented by the presence of
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cytokines such as interleukin 2 (IL-2), IL-4, and IL-7 (Lenardo et al,
1999). Telford et al (1997) have shown in a mouse model that
antigen-withdrawal-induced apoptosis is independent of Fas and
TNFRI but is regulated mainly by CD30 antigen.
CD30 is normally detectable on a small number of immunoblasts
located in the perifollicular region around germinal centers (Falini
et al, 1995). In addition, CD30 is expressed by Reed-Sternberg cells
in virtually all cases of classical Hodgkin's lymphoma and by tumor
cells in anaplastic large cell lymphoma (ALCL) (Falini et al, 1995).
CD30 ligand (CD30L) is expressed on neutrophils, histiocytes,
eosinophils, and a small subset of activated T cells (Smith et al,
1993). Accumulating evidence suggests that CD30 acts as a negative
regulator of T cells. CD30 knock out mice show thymic
hyperplasia and a defect in negative selection of T cells responding
to self-antigens in the thymus (Amakawa et al, 1996). In a murine
model, CD30 antigen is protective against autoimmune type I
diabetes mediated by autoreactive CD8+ cells (Kurts et al, 1999),
and Chiarle et al (1999) demonstrated enhanced cell death of T cells
that express CD30 in response to antigen stimulation and CD30
costimulation.
As CD30+ cutaneous LPD represents clonal expansion of an
abnormal T cell clone, the normal fate of these T cells should be
elimination by one of the mechanisms mentioned above. The early
lesions do regress, but the mechanism of spontaneous regression
seen in these lesions is unknown. We believe that Fas and CD30 are
two signaling pathways that can mediate regression. The tumor
cells in CD30+ cutaneous LPD have been shown to express Fas
(Paulli et al, 1998; Mori et al, 1999). CD30L expression shows a
correlation with regression of the lesions suggesting a role for CD30
activation in the usual regression of cutaneous CD30+ lymphomas
(Mori et al, 1999).
Until now, there has not been a functional study of the responses
of tumor cells from cutaneous CD30+ LPD to the activation of
TNF receptor superfamily members including Fas and CD30, due
to the lack of tumor cell lines. We developed three cell lines from
cutaneous tumors and circulating tumor cells of two patients who
had lymphomatoid papulosis (LyP) and then progressed to fatal
systemic lymphomas during the course of their disease (Davis et al,
1992; Kadin et al, 1994; Schiemann et al, 1999). We investigated
the responses of these cell lines to Fas and CD30 activation in vitro.
We also investigated the intracellular signaling mechanisms
associated with CD30 activation, including nuclear factor kappa
B (NF-kB) and mitogen-activated protein kinase (MAPK), in order
to understand the mechanism of disease progression and to develop
novel therapies targeting these pathways in advanced disease
originating from cutaneous CD30+ LPD.
MATERIALS AND METHODS
Cell lines JK, Mac-1, and Mac-2 A are cutaneous ALCL cell lines (Kadin
et al, 1994). The JK cell line was developed from an advanced skin tumor of
a patient who progressed over a 10 y period from LyP to ALCL
(Schiemann et al, 1999); the clonal relationship of LyP and ALCL lesions
has been demonstrated (Chott et al, 1996). JK cells have the same
phenotype as the original tumor (CD30+, CD3+). Mac-1 and Mac-2 A are
clonally related cell lines derived from a CD30+ cutaneous T cell ALCL
that had progressed from LyP over a 17 y period. Details of the cell lines
have been reported elsewhere (Davis et al, 1992; Kadin et al, 1994).
Immunohistochemistry Immunohistochemical staining for CD30L
was performed on 4 mm sections of formalin-®xed paraf®n-embedded
material as previously described (Mori et al, 1999). Sections were stained
with the M80 antibody against CD30L kindly provided by Immunex,
Seattle, WA.
Antibodies and inhibitors HeFi-1 (NCI, Frederick, MD) is a mouse
monoclonal IgG1 antibody raised against human CD30 (Hecht et al, 1985).
HeFi-1 has an agonistic effect on the CD30 pathway mimicking the effects
of CD30L. Mouse IgG1 (Sigma, St. Louis, MO) is used as an isotype-
speci®c control. SN50 is a synthetic peptide that is cell permeable and
inhibits NF-kB by competing with the nuclear localization sequence of
NF-kB (p50) (Lin et al, 1995). SN50M is a synthetic peptide mutated at the
nuclear localization sequence site so that it can be used as a negative control
for SN50. U0126 is a selective inhibitor of MEK1 and MEK2 (Favata et al,
1998). All three chemicals were purchased from Calbiochem (San Diego,
CA). Anti-human Fas antibody with agonistic properties was obtained from
R&D Systems, Minneapolis, MN (clone DX2.1).
3H-Thymidine incorporation assay Tumor cells were grown in
round-bottomed 96 well plates in triplicate. Following incubation with
soluble antibodies and 10% fetal bovine serum in RPMI, the wells were
pulsed with 1 mCi 3H-thymidine during the ®nal 12 h. Tumor cells were
harvested with the aid of a cell harvester (PhD Systems, Cambridge, MA)
and radioactivity was measured with a scintillation counter (Wallac 1409;
Wallac, Gaithersburg, MD).
Electrophoretic mobility shift experiments Nuclear extracts from
tumor cell lines were obtained before and after stimulation with HeFi-1
antibody for 1 h. The extracts were incubated with 32P end-labeled NF-kB
binding site oligoprobes (5¢-AGCTTGGGGTATTTCCAGCCG-3¢),
mutant oligoprobes (5¢-AGCTTGGCATAGGTCCAGCCG-3¢), and
excess cold oligoprobes, and were run on a nondenaturing 6%
polyacrylamide gel. Gels were dried and exposed to ®lm (NF-kB/Rel T
cell activation Gelshift kit, Geneka, Montreal, Canada). Nuclear extracts
were prepared as follows: 10 3 106 cells were incubated with HeFi-1 for
1 h, and then washed in phosphate-buffered saline and lyzed in 400 ml cold
buffer A [10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl ¯uoride (PMSF), pH
7.9]. Samples were kept on ice for 15 min, and then vortexed for 10 s.
Nuclei were pelleted by microcentrifugation for 10 s. Pellets were re-
suspended in 40 ml buffer B (20 mM HEPES, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM ethylenediamine tetraacetic acid, 0.5 mM DTT,
0.2 mM PMSF) and incubated on ice for 20 min. Nuclei were pelleted by
spinning for 3 min at 4°C. Supernatants were aliquoted and stored at
±80°C.
MAPK kinase assay MAPK activity was determined by the MAPK
kinase assay kit according to the manufacturer's recommended protocols
(New England Biolabs, Beverly, MA). Brie¯y, whole cell lysates were
immunoprecipitated with an anti-MAPK antibody. The immuno-
precipitated proteins were used in a nonradioactive in vitro kinase assay.
A Gst-Elk1 fusion peptide was used as a substrate for the detection of kinase
activity in the immunoprecipitates. Following the kinase assay,
phosphorylation of the Gst-Elk1 substrate was measured by Western
blots using an antiphopho-Elk1 antibody for detection.
RESULTS
Immunohistochemical staining for CD30L Immuno-
histochemical staining con®rmed the presence of CD30L in tissue
sections from the LyP mainly in the cytoplasm of 10%-20% of large
atypical cells, including Reed-Sternberg-like cells, and some
smaller cells (Fig 1). Staining of CD30L appeared to be associated
with degenerative changes in some cells of the case from which
Mac-1 and Mac-2 A cell lines were derived.
Figure 1. Immunohistochemical staining of CD30L. Immunohisto-
chemistry with antibody M80 reveals staining of Reed-Sternberg-like cells
and some smaller cells in LyP lesions of patients from whom Mac-1 and
Mac-2 A cells (a and b) and JK cells (c and d) were derived.
VOL. 115, NO. 6 DECEMBER 2000 CD30 SIGNALING IN CUTANEOUS ALCL 1035
Effects of CD30 activation on cell proliferation In order to
analyze the functional status of the CD30/CD30L signaling
pathway in the cell lines representing advanced cutaneous ALCL,
we used a monoclonal antibody, HeFi-1 (Hecht et al, 1985), that
recognizes the CD30L binding domain of CD30 antigen and leads
to activation of the CD30 signaling cascade. We and others have
previously shown that this antibody mimics the action of CD30L
and is an effective growth inhibitor of tumor cells of systemic
CD30+ ALCL, both in vitro and in vivo (Tian et al, 1995; Pfeifer
et al, 1999). Upon activation of the CD30 signaling pathway by
HeFi-1, Mac-1 and Mac-2 A cell lines showed proliferative
responses whereas the JK cell line did not change its proliferative
activity, as measured in a 3H-thymidine incorporation assay (Fig 2).
We also tested the effects of CD30 activation of the Karpas 299 cell
line, a systemic ALCL cell line with the translocation t(2; 5)(p23;
q35), and observed a 50% growth inhibition as previously reported
(Pfeifer et al, 1999) (not shown).
Effects of Fas activation on cell growth In order to assess
their sensitivity to Fas-mediated apoptosis in vitro, the cell lines
were incubated with a Fas agonistic antibody (clone DX2.1, R&D
systems) for 24 h, and then pulsed with 3H-thymidine for 12 h. All
three cell lines demonstrated signi®cant growth inhibition in
response to Fas activation whereas control cells incubated with an
isotype-speci®c mouse IgG were unaffected (Fig 3). Cell viability
was independently assessed by trypan blue vital staining and cell
death was con®rmed (not shown). As expected, the Karpas 299 cell
line, which is known to be resistant to Fas-mediated apoptosis, did
not show inhibition of cell growth upon Fas activation (not
shown).
Role of NF-kB in CD30 signaling Following the assessment of
the responses of the cell lines to CD30 and Fas activation, we
wanted to analyze the downstream effectors of the CD30 signaling
pathway. The immediate transducers of CD30 signaling are the
TNF-associated factors (TRAFs). TRAF-1, TRAF-2, TRAF-3,
and TRAF-5 are known to bind the intracytoplasmic domain of
CD30 (Arch et al, 1998). TRAF-2 is known to activate NF-kB and
the c-jun N-terminal kinase (JNK) pathways (Song et al, 1997). In
addition, in some cell lines MAPK is activated by CD30 signaling
(Wendtner et al, 1995). As NF-kB and MAPK pathways are
important for numerous cell functions including cell survival,
proliferation, and cytokine secretion, we thought these two
pathways would be most important to explain the proliferative
responses observed by CD30 activation (Hunter, 1995; Barnes and
Karin, 1997; Sonenshein, 1997). As the JNK pathway is usually
associated with stress responses and apoptosis, we did not pursue
that pathway (Ip and Davis, 1998). The downstream signaling
pathways associated with CD30 signaling and the sites of action of
the inhibitors used in the study are illustrated in Fig 4.
We measured the nuclear NF-kB activity of cell lines Mac-1 and
Mac-2 A before and after CD30 activation. Nuclear extracts were
obtained from cells that were incubated with antibody HeFi-1. The
nuclear extracts were incubated with 32P-labeled oligoprobes
representing NF-kB binding sites and run on a polyacrylamide
gel. Gelshift experiments showed minimal constitutive NF-kB
activity in Mac-1 and Mac-2 A cell lines. In contrast, following
incubation with HeFi-1 for 30 min, both cell lines showed strong
NF-kB activation (Fig 5). The speci®city of the binding was tested
by addition of excess cold probe and excess cold mutant probe.
We then investigated the NF-kB pathway by use of a speci®c
inhibitor of NF-kB, SN50 (Lin et al, 1995). Mac-1 and Mac-2 A
cell lines demonstrated inhibition of cell growth within 24 h when
incubated with the NF-kB inhibitor SN50 at 50 mg per ml
concentration in the presence of HeFi-1 (1 mg per ml). The JK
cell line showed no response to the NF-kB inhibitor (Fig 6). As a
negative control for SN50, we incubated the cells with SN50M,
which is a synthetic peptide that differs from SN50 in just two
amino acids that correspond to the nuclear localization sequence.
Figure 2. Proliferative responses to CD30 activation. Proliferative
activity was measured by a 3H-thymidine incorporation assay. Cutaneous
CD30+ ALCL cell lines JK, Mac-1, and Mac-2 A were incubated in 10%
fetal bovine serum and RPMI in the presence of CD30 activating antibody
HeFi-1 (1 mg per ml) for 48 h and pulsed with 3H-thymidine (1 mCi) during
the last 12 h of incubation. Control cells were incubated with isotype-
speci®c mouse IgG. The counts are shown as percentages compared to
controls (mean 6 SD). The experiments were performed in triplicate and
repeated at least three times. A representative experiment is shown.
*p < 0.05.
Figure 3. Fas-mediated growth inhibition of the cell lines. Effects of
Fas activation on the cell lines was determined by 3H-thymidine
incorporation assays following incubation with a Fas agonist antibody for
24 h. The counts are shown as percentages compared to controls (mean
6 SD). The experiments were performed in triplicate and repeated at least
three times. A representative experiment is shown. *p < 0.05.
Figure 4. Signaling pathways triggered by CD30 activation. This
cartoon depicts intracellular signaling by CD30 activation through TRAFs,
NF-kB, and MAPK. The sites of action of the inhibitors used in this study
are shown. GFR, growth factor receptor.
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Incubation with SN50M caused no changes in the responses of the
cells, con®rming the speci®city of responses to SN50 (not shown).
Role of MAPK in CD30 signaling Another candidate pathway
to explain the responses of the cell lines to CD30 activation is
MAPK. As in the NF-kB experiments, we measured the activity of
MAPK before and after CD30 activation by a kinase assay, and then
tested the effects of inhibitors of the MAPK pathway. The cell lines
were starved in serum-free media for 24 h before the experiments.
CD30 activation was achieved by incubating the cell lines with the
HeFi-1 antibody for 10 min. JK and Mac-1 cell lines had weak to
minimal baseline MAPK activities, which were enhanced by CD30
activation, whereas Mac-2 A had a high constitutive MAPK activity
that was slightly increased by CD30 activation (Fig 7).
We also tested the effects of MAPK inhibition on the
proliferative properties of the cell lines by using a recently
described speci®c MEK1 inhibitor, U0126 (Favata et al, 1998).
The cells were incubated with 1 or 10 mM of the inhibitor for
30 min, and then HeFi-1 was added. We measured 3H-thymidine
incorporation after 24 h. At 1 mM, all cell lines demonstrated
signi®cant growth inhibition. When 10 mM of the inhibitor was
added, the cell lines were almost completely growth inhibited
(Fig 8).
DISCUSSION
In this study we demonstrate that activation of CD30 in cutaneous
CD30+ ALCL cell lines does not induce growth inhibition; instead
it causes proliferation of the Mac-1 and Mac-2 A cell lines. Others
have shown that activation of CD30 by a monoclonal antibody
could induce sustained proliferation of human autoreactive gd T
cells in the presence of recombinant IL-2 (Leca et al, 1994). Those
cells were not transformed, however, and cell growth arrest
occurred upon removal of the antibody. In contrast, our cell lines
express an ab rather than gd phenotype and do not undergo
growth arrest upon removal of the CD30 activating antibody,
HeFi-1. Cutaneous and systemic CD30+ ALCL cell lines appear to
have opposite growth responses to CD30 activation as CD30
activation is an inhibitory signal for systemic ALCL cell lines (Gruss
et al, 1994). Cutaneous and systemic ALCL also have distinct
pathways of pathogenesis. Systemic ALCL cell lines harbor the
Figure 5. Activation of NF-kB by CD30 activation. Nuclear extracts
obtained from Mac-1 and Mac-2 A cell lines were incubated with 32P-
labeled oligoprobes (H), (H) + excess cold oligoprobes (C), and (H) +
excess cold mutant oligoprobes (M), with or without HeFi-1 for 1 h. The
arrows show the speci®c bands, which are retarded due to the binding of
the probes to nuclear proteins, and the unbound probes at the bottom of
the gel. The remaining bands are due to nonspeci®c binding of the probe to
other nuclear proteins. Unlike the speci®c bands, which disappear when
excess cold unlabeled oligoprobes are added (C), these bands do not
disappear. A representative experiment is shown.
Figure 6. Effects of NF-kB inhibition during CD30 activation. The
NF-kB inhibitor SN50 was added 30 min before the addition of HeFi-1.
3H-Thymidine was added in the last 12 h of the 24 h incubation. The
results are shown as percentages of the control values (mean 6 SD). The
experiments were performed in triplicate and repeated at least three times.
A representative experiment is shown. *p < 0.05.
Figure 7. Activation of MAPK by CD30 signaling. MAPK activity
was measured after CD30 activation for 10 min, and control cells were
incubated with isotype-speci®c mouse IgG. CD30 activation was achieved
by HeFi-1 antibody. Mac-2 A cell line was also incubated with the MEK1
inhibitor U0126 for 10 min and the MAPK activity was measured. Equal
loading of wells was con®rmed by measuring the protein concentration of
the cell lysates before immunoprecipitation, and staining the blotted
membranes for protein.
Figure 8. Inhibition of MAPK activity causes growth inhibition.
Growth responses of the cell lines to inhibition of MEK1 were tested at
two different doses of the MEK1 and MEK2 inhibitor, U0126.The
inhibitor was added 30 min before the addition of HeFi-1. Responses are
shown as percentages of the control values (mean 6 SD). The experiments
were performed in triplicate and repeated at least three times. A
representative experiment is shown. *p < 0.05.
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translocation t(2; 5)(p23; q35), which causes overexpression of the
NPM/ALK fusion protein (ALK) leading to the unregulated
growth of tumor cells (Morris et al, 1994). ALK is characteristically
absent in cutaneous ALCL (DeCoteau et al, 1996). Therefore,
cutaneous and systemic ALCLs have been identi®ed as separate
entities in the new lymphoma classi®cations (Jaffe et al, 1999).
There is limited information regarding the etiology and biology
of CD30+ cutaneous ALCL. In general, the primary cutaneous
LPD constitute a spectrum of diseases ranging from LyP to
cutaneous ALCL, which have an excellent prognosis (Paulli et al,
1995). A small percentage of these diseases (approximately 5%),
however, progress to fatal systemic lymphomas (Beljaards and
Willemze, 1992). The cell lines we used in our study are
representative of such uncommon cases that ®rst present as LyP
and later progress to fatal systemic lymphomas.
A well-known phenomenon associated with cutaneous
CD30+ LPD is the frequent occurrence of spontaneous regression
(Willemze et al, 1993). In a recent study, a positive correlation was
demonstrated between regression and CD30L expression levels
measured by semiquantitative reverse transcriptase polymerase
chain reaction in cases of LyP and primary cutaneous ALCL,
suggesting that CD30 activation may play a role in the spontaneous
regression of such lesions (Mori et al, 1999). In this study, we
con®rmed the presence of CD30L in the LyP skin lesions of each
patient by immunohistochemistry. Our results raise the possibility
that the development of resistance to the CD30L-mediated growth
inhibitory effects, or even transformation of the tumor response to
one of cellular proliferation in response to CD30 activation, may
provide a mechanism for tumor cell escape from the normal growth
regulatory responses and support progression of LyP to ALCL.
Recently, Fas expression was demonstrated in cutaneous
CD30+ LPD (Paulli et al, 1998; Mori et al, 1999). A functional
role for Fas-mediated apoptosis in the regression of these lesions,
however, has not been shown. We investigated the susceptibility of
our cutaneous ALCL lines to Fas-induced apoptosis. As all three
cell lines were sensitive to Fas-induced apoptosis, we conclude that
the Fas signaling pathway is unlikely to play a role in the
progression of LyP to ALCL.
In order to gain insight into the downstream effects of CD30
activation, we investigated some pathways that are involved in the
CD30/CD30L signaling system. CD30 activation is known to
cause upregulation of NF-kB, utilizing the TRAFs as adapter
molecules (Duckett et al, 1997; Song et al, 1997). Constitutive
activation of NF-kB has been demonstrated in Hodgkin's
lymphoma cell lines and has been implicated in their survival and
tumorigenicity (Bargou et al, 1997). We were interested to
compare cutaneous ALCL cell lines with Hodgkin's lymphoma as
these diseases have similar morphologic and immunohistochemical
features (Davis et al, 1992; Kadin, 1993). In addition, patients with
LyP sometimes develop Hodgkin's lymphoma (Davis et al, 1992;
Wang et al, 1992; Cabanillas et al, 1995). Our study shows that,
unlike Hodgkin's lymphoma, cutaneous ALCL cell lines do not
have high constitutive NF-kB activity.
The ERK (MAPK) pathway is also known to be activated by
members of the TNF receptor family, including CD30 (Wendtner
et al, 1995; Wallach et al, 1999). In a previous study by Wendtner
et al (1995), CD30 signaling led to MAPK activation in the T-cell-
type Hodgkin's lymphoma cell line HDLM-2, but not in the
systemic ALCL cell line Karpas 299 nor in the B-cell-type
Hodgkin's lymphoma cell line KMH2. Interestingly, the HDLM-2
cell line showed increased proliferation in response to CD30
activation whereas Karpas 299 was growth inhibited. Here, we
demonstrate that the MAPK (ERK) pathway is activated by CD30
signaling in cutaneous T cell ALCL cell lines Mac-1 and JK as well,
whereas Mac-2A has high constitutive expression of MAPK;
inhibition of MAPK is an effective way of inhibiting growth of
these cell lines.
The mechanism of altered responsiveness to CD30 activation in
the cell lines from advanced cutaneous ALCL is unclear. We have
shown that, in the systemic ALCL cell line Karpas 299, CD30
activation causes cell cycle arrest despite activation of the NF-kB
pathway (Levi et al, submitted for publication). The proliferative
response seen in the Mac-1 and Mac-2 A cell lines was at least partly
due to MAPK and NF-kB activation by CD30 signaling. In this
study, we demonstrated that MAPK activation is one of the major
effectors of CD30 signaling in these cutaneous ALCL cell lines.
It has been shown that mammalian cells can be transformed by
transfection with constitutively active MAPK (Mansour et al,
1994). In addition, inhibition of the MAPK activity in mice
xenografted with colon tumors causes inhibition of tumor growth
(Sebolt-Leopold et al, 1999). We believe that inhibitors of the
MAPK pathway can become useful in the treatment of various
cancers as the Ras pathway, which is upstream of the MAPK, is
frequently mutated in human cancers (Macara et al, 1996; Hunter,
1997).
Based on this study and previous work, we propose a model of
progression of LyP to systemic lymphoma by several steps that
abolish the physiologic inhibitory mechanisms that are important
for the regulation of the immune system such as transforming
growth factor beta (TGF-b) and CD30 (Fig 9). According to this
Figure 9. Hypothesis for mechanisms of pro-
gression of cutaneous CD30+ LPD. The
cartoon depicts the growth inhibitory effects of
CD30L, Fas, and TGF-b on LyP in regressing
skin lesions. Our studies indicate that tumor pro-
gression to ALCL is in part due to escape from
growth inhibition through altered CD30 signaling
and mutations of the TGF-b receptor (Knaus et al,
1996; Schiemann et al, 1999).
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model, an unknown antigenic stimulus triggers clonal expansion of
T cells, which form cutaneous in®ltrates that manifest as multiple
regressing skin lesions of LyP. The LyP cells are usually eliminated
by growth inhibitory mechanisms such as Fas, CD30, and TGF-b.
Therefore, the lesions spontaneously regress in weeks to months.
After recurrent episodes of spontaneously regressing LyP lesions, a
small number of patients will develop large lesions that require
treatment. A few of these patients will have extracutaneous spread
of the disease, which may be resistant to chemotherapy. We
hypothesize that in these patients disease progression from LyP to
ALCL is associated with impairment of the normal T cell growth
inhibitory mechanisms that would otherwise cause regression of
these lesions. In these and prior experiments, we tested three of the
best characterized inhibitory mechanisms that regulate the T cell
arm of the immune system - Fas, CD30, and TGF-b - and
demonstrated a selective role for CD30 in the context of escape
from growth inhibitory mechanisms. In the case of TGF-b,
resistance was shown to be mediated by mutations of the type I (JK)
and type II (Mac-2 A) receptors (Knaus et al, 1996; Schiemann et al,
1999). These mutations were due to a deletion that eliminates the
initiating methionine required for translation of the type I receptor
in the JK cell line, and due to a single nucleotide substitution (A to
G) in the kinase domain of the type II receptor in the Mac-2 A cell
line, whereas Mac-1, which is inhibited by TGF-b, had no TGF-b
receptor mutation. Both mutations were present in the corres-
ponding tissue sections obtained from the patients. Preliminary data
from our laboratory indicate the presence of mutations in CD30
that may alter CD30 signaling and could explain the proliferative
responses of Mac-1 and Mac-2 A cells and failure of JK cells to
respond to HeFi-1. At present no cell lines from regressing lesions
are available for comparison but this is a long-term goal. The fact
that both TGF-b and CD30 signaling systems were noninhibitory
suggests that abrogation of both pathways may be required for the
progression of these lymphomas to fatal systemic disease.
In summary, we have demonstrated that in addition to evading
TGF-b-mediated growth control, advanced CD30+ ALCL cell
lines can be resistant to growth inhibition by CD30 signaling, but
retain susceptibility to Fas-induced cell death. We also identi®ed
the ERK (MAPK) pathway inhibitors as candidates for novel
therapies against these advanced cutaneous ALCL.
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